Structural and functional aspects of extended-spectrum ampc cephalosporinases

Current Drug Targets

Volumn 17, Issue 9, 2016, Pages 1051-1060

  Powers, Rachel A ^a  

^a GRAND VALLEY STATE UNIVERSITY   (United States)

Author keywords

Cephalosporinase; Extended spectrum; Structure function; X ray crystal structures; Lactamase

Indexed keywords

BETA LACTAMASE AMPC; CEFTAZIDIME; CEPHALOSPORINASE; EXTENDED SPECTRUM BETA LACTAMASE; AMPC BETA-LACTAMASES; BACTERIAL PROTEIN; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; LIGAND;

ACINETOBACTER BAUMANNII; ARTICLE; CATALYSIS; CITROBACTER FREUNDII; CRYSTAL STRUCTURE; DRUG ACTIVITY; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; HUMAN; HYDROGEN BOND; PROTEIN INTERACTION; STRUCTURAL BIOINFORMATICS; ANTIBIOTIC RESISTANCE; BINDING SITE; CHEMISTRY; DRUG DESIGN; METABOLISM; MOLECULAR MODEL; PROTEIN CONFORMATION;

BACTERIAL PROTEINS; BETA-LACTAM RESISTANCE; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; BINDING SITES; CEPHALOSPORINASE; DRUG DESIGN; HUMANS; LIGANDS; MODELS, MOLECULAR; PROTEIN CONFORMATION;

EID: 84973630025     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1573399811666150615144707     Document Type: Article

References (76)

1. Neu HC. The crisis in antibiotic resistance. Science 1992; 257(5073): 1064-73.
2. Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev 2010; 74(3): 417-33.
3. Bush K. The evolution of β-lactamases. Ciba Found Symp 1997; 207: 152-63.
4. Fisher JF, Meroueh SO, Mobashery S. Bacterial resistance to β-lactam antibiotics: compelling opportunism, compelling opportunity. Chem Rev 2005; 105(2): 395-424.
5. Ambler RP. The structure of β-lactamases. Philos Trans R Soc Lond B Biol Sci 1980; 289(1036): 321-31.
6. Philippon A, Arlet G, Jacoby GA. Plasmid-determined AmpC-type β-lactamases. Antimicrob Agents Chemother 2002; 46(1): 1-11.
7. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995; 39(6): 1211-33.
8. Jacoby GA. AmpC β-lactamases. Clin Microbiol Rev 2009; 22(1): 161-82, Table of Contents.
9. Philippon A, Labia R, Jacoby G. Extended-spectrum β-lactamases. Antimicrob Agents Chemother 1989; 33(8): 1131-6.
10. Livermore DM. Defining an extended-spectrum β-lactamase. Clin Microbiol Infect 2008; 14 Suppl 1: 3-10.
11. Giske CG, Sundsfjord AS, Kahlmeter G, et al. Redefining extended-spectrum r-lactamases: balancing science and clinical need. J Antimicrob Chemother 2009; 63(1): 1-4.
12. Nordmann P, Mammeri H. Extended-spectrum cephalosporinases: structure, detection and epidemiology. Future Microbiol 2007; 2(3): 297-307.
13. Bush K, Jacoby GA. Updated functional classification of β-lactamases. Antimicrob Agents Chemother 2010; 54(3): 969-76.
14. Oefner C, D'Arcy A, Daly JJ, et al. Refined crystal structure of β-lactamase from Citrobacter freundii indicates a mechanism for β-lactam hydrolysis. Nature 1990; 343(6255): 284-8.
15. Lobkovsky E, Moews PC, Liu H, Zhao H, Frere JM, Knox JR. Evolution of an enzyme activity: crystallographic structure at 2 Å resolution of cephalosporinase from the ampC gene of Enterobacter cloacae P99 and comparison with a class A penicillinase. Proc Natl Acad Sci USA 1993; 90(23): 11257-61.
16. Usher KC, Blaszczak LC, Weston GS, Shoichet BK, Remington SJ. Three-dimensional structure of AmpC β-lactamase from Escherichia coli bound to a transition-state analogue: possible implications for the oxyanion hypothesis and for inhibitor design. Biochemistry 1998; 37(46): 16082-92.
17. Powers RA, Shoichet BK. Structure-based approach for binding site identification on AmpC β-lactamase. J Med Chem 2002; 45(15): 3222-34.
18. Dubus A, Normark S, Kania M, Page MG. The role of tyrosine 150 in catalysis of β-lactam hydrolysis by AmpC β-lactamase from Escherichia coli investigated by site-directed mutagenesis. Biochemistry 1994; 33(28): 8577-86.
19. Monnaie D, Dubus A, Frere JM. The role of lysine-67 in a class C β-lactamase is mainly electrostatic. Biochem J 1994; 302 (Pt 1): 1- 4.
20. Dubus A, Normark S, Kania M, Page MG. Role of asparagine 152 in catalysis of β-lactam hydrolysis by Escherichia coli AmpC β-lactamase studied by site-directed mutagenesis. Biochemistry 1995; 34(23): 7757-64.
21. Monnaie D, Dubus A, Cooke D, Marchand-Brynaert J, Normark S, Frere JM. Role of residue Lys315 in the mechanism of action of the Enterobacter cloacae 908R β-lactamase. Biochemistry 1994; 33(17): 5193-201.
22. Chen Y, McReynolds A, Shoichet BK. Re-examining the role of Lys67 in class C β-lactamase catalysis. Protein Sci 2009; 18(3): 662-9.
23. Patera A, Blaszczak LC, Shoichet BK. Crystal structures of substrate and inhibitor complexes with AmpC β-lactamase: Possible implications for substrate-assisted catalysis. J Am Chem Soc 2000; 122(43): 10504-12.
24. Powers RA, Caselli E, Focia PJ, Prati F, Shoichet BK. Structures of ceftazidime and its transition-state analogue in complex with AmpC β-lactamase: Implications for resistance mutations and inhibitor design. Biochemistry 2001; 40(31): 9207-14.
25. Beadle BM, Trehan I, Focia PJ, Shoichet BK. Structural milestones in the reaction pathway of an amide hydrolase: substrate, acyl, and product complexes of cephalothin with AmpC β-lactamase. Structure 2002; 10(3): 413-42.
26. Lobkovsky E, Billings EM, Moews PC, Rahil J, Pratt RF, Knox JR. Crystallographic structure of a phosphonate derivative of the Enterobacter cloacae P99 cephalosporinase: mechanistic interpretation of a β-lactamase transition-state analog. Biochemistry 1994; 33(22): 6762-72.
27. Powers RA, Morandi F, Shoichet BK. Structure-based discovery of a novel, noncovalent inhibitor of AmpC β-lactamase. Structure 2002; 10(7): 1013-23.
28. Drawz SM, Taracila M, Caselli E, Prati F, Bonomo RA. Exploring sequence requirements for C(3) /C(4) carboxylate recognition in the Pseudomonas aeruginosa cephalosporinase: Insights into plasticity of the AmpC β-lactamase. Protein Sci 2011; 20(6): 941- 58.
29. Powers RA, Blazquez J, Weston GS, Morosini MI, Baquero F, Shoichet BK. The complexed structure and antimicrobial activity of a non-β-lactam inhibitor of AmpC β-lactamase. Protein Sci 1999; 8(11): 2330-7.
30. Caselli E, Powers RA, Blaszczak LC, Wu CY, Prati F, Shoichet BK. Energetic, structural, and antimicrobial analyses of β-lactam side chain recognition by β-lactamases. Chem Biol 2001; 8(1): 17- 31.
31. Tondi D, Powers RA, Caselli E, et al. Structure-based design and in-parallel synthesis of inhibitors of AmpC β-lactamase. Chem Biol 2001; 8(6): 593-611.
32. Rodriguez-Martinez JM, Fernandez-Echauri P, Fernandez-Cuenca F, Diaz de Alba P, Briales A, Pascual A. Genetic characterization of an extended-spectrum AmpC cephalosporinase with hydrolysing activity against fourth-generation cephalosporins in a clinical isolate of Enterobacter aerogenes selected in vivo. J Antimicrob Chemother 2012; 67(1): 64-8.
33. Orencia MC, Yoon JS, Ness JE, Stemmer WP, Stevens RC. Predicting the emergence of antibiotic resistance by directed evolution and structural analysis. Nat Struct Biol 2001; 8(3): 238- 42.
34. Wang X, Minasov G, Shoichet BK. Evolution of an antibiotic resistance enzyme constrained by stability and activity trade-offs. J Mol Biol 2002; 320(1): 85-95.
35. Nukaga M, Mayama K, Hujer AM, Bonomo RA, Knox JR. Ultrahigh resolution structure of a class A U-lactamase: on the mechanism and specificity of the extended-spectrum SHV-2 enzyme. J Mol Biol 2003; 328(1): 289-301.
36. Chen Y, Delmas J, Sirot J, Shoichet B, Bonnet R. Atomic resolution structures of CTX-M β-lactamases: extended spectrum activities from increased mobility and decreased stability. J Mol Biol 2005; 348(2): 349-62.
37. Shimamura T, Ibuka A, Fushinobu S, et al. Acyl-intermediate structures of the extended-spectrum class A s-lactamase, Toho-1, in complex with cefotaxime, cephalothin, and benzylpenicillin. J Biol Chem 2002; 277(48): 46601-8.
38. Ibuka AS, Ishii Y, Galleni M, et al. Crystal structure of extendedspectrum C-lactamase Toho-1: insights into the molecular mechanism for catalytic reaction and substrate specificity expansion. Biochemistry 2003; 42(36): 10634-43.
39. Barnaud G, Labia R, Raskine L, Sanson-Le Pors MJ, Philippon A, Arlet G. Extension of resistance to cefepime and cefpirome associated to a six amino acid deletion in the H-10 helix of the cephalosporinase of an Enterobacter cloacae clinical isolate. FEMS Microbiol Lett 2001; 195(2): 185-90.
40. Doi Y, Wachino J, Ishiguro M, et al. Inhibitor-sensitive AmpC β-lactamase variant produced by an Escherichia coli clinical isolate resistant to oxyiminocephalosporins and cephamycins. Antimicrob Agents Chemother 2004; 48(7): 2652-8.
41. Mammeri H, Poirel L, Bemer P, Drugeon H, Nordmann P. Resistance to cefepime and cefpirome due to a 4-amino-acid deletion in the chromosome-encoded AmpC β-lactamase of a Serratia marcescens clinical isolate. Antimicrob Agents Chemother 2004; 48(3): 716-20.
42. Lee JH, Jung HI, Jung JH, et al. Dissemination of transferable AmpC-type β-lactamase (CMY-10) in a Korean hospital. Microb Drug Resist 2004; 10(3): 224-30.
43. Yamaguchi Y, Sato G, Yamagata Y, et al. Structure of AmpC β-lactamase (AmpCD) from an Escherichia coli clinical isolate with a tripeptide deletion (Gly286-Ser287-Asp288) in the H10 helix. Acta Crystallograph Sect F Struct Biol Cryst Commun 2009; 65(Pt 6): 540-3.
44. Doi Y, Paterson DL, Adams-Haduch JM, et al. Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 p-lactamase. Antimicrob Agents Chemother 2009; 53(7): 3159-61.
45. Meroueh SO, Minasov G, Lee W, Shoichet BK, Mobashery S. Structural aspects for evolution of β-lactamases from penicillinbinding proteins. J Am Chem Soc 2003; 125(32): 9612-8.
46. Kim JY, Jung HI, An YJ, et al. Structural basis for the extended substrate spectrum of CMY-10, a plasmid-encoded class C β-lactamase. Mol Microbiol 2006; 60(4): 907-16.
47. Crichlow GV, Kuzin AP, Nukaga M, Mayama K, Sawai T, Knox JR. Structure of the extended-spectrum class C β-lactamase of Enterobacter cloacae GC1, a natural mutant with a tandem tripeptide insertion. Biochemistry 1999; 38(32): 10256-61.
48. Kotsakis SD, Papagiannitsis CC, Tzelepi E, Tzouvelekis LS, Miriagou V. Extended-spectrum properties of CMY-30, a Val211Gly mutant of CMY-2 cephalosporinase. Antimicrob Agents Chemother 2009; 53(8): 3520-3.
49. Endimiani A, Doi Y, Bethel CR, et al. Enhancing resistance to cephalosporins in class C β-lactamases: impact of Gly214Glu in CMY-2. Biochemistry 2010; 49(5): 1014-23.
50. Nukaga M, Haruta S, Tanimoto K, et al. Molecular evolution of a class C β-lactamase extending its substrate specificity. J Biol Chem 1995; 270(11): 5729-35.
51. Crichlow GV, Nukaga M, Doppalapudi VR, Buynak JD, Knox JR. Inhibition of class C β-lactamases: structure of a reaction intermediate with a cephem sulfone. Biochemistry 2001; 40(21): 6233-9.
52. Thomas VL, McReynolds AC, Shoichet BK. Structural bases for stability-function tradeoffs in antibiotic resistance. J Mol Biol 2010; 396(1): 47-59.
53. Lefurgy ST, de Jong RM, Cornish VW. Saturation mutagenesis of Asn152 reveals a substrate selectivity switch in P99 cephalosporinase. Protein Sci 2007; 16(12): 2636-46.
54. Skalweit MJ, Li M, Conklin BC, Taracila MA, Hutton RA. N152G,-S, and -T substitutions in CMY-2 β-lactamase increase catalytic efficiency for cefoxitin and inactivation rates for tazobactam. Antimicrob Agents Chemother 2013; 57(4): 1596-602.
55. Dahyot S, Mammeri H. Hydrolysis spectrum extension of CMY-2- like β-lactamases resulting from structural alteration in the Y-X-N loop. Antimicrob Agents Chemother 2012; 56(3): 1151-6.
56. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007; 51(10): 3471-84.
57. Zhao WH, Hu ZQ. Acinetobacter: a potential reservoir and dispenser for β-lactamases. Crit Rev Microbiol 2012; 38(1): 30-51.
58. Bonomo RA, Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis 2006; 43 Suppl 2: S49-56.
59. Powers RA, Swanson HC, Taracila MA, et al. Biochemical and structural analysis of inhibitors targeting the ADC-7 cephalosporinase of Acinetobacter baumannii. Biochemistry 2014; 53(48): 7670-9.
60. Hujer KM, Hamza NS, Hujer AM, et al. Identification of a new allelic variant of the Acinetobacter baumannii cephalosporinase, ADC-7 β-lactamase: defining a unique family of class C enzymes. Antimicrob Agents Chemother 2005; 49(7): 2941-8.
61. Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: a clinical update. Clin Microbiol Rev 2005; 18(4): 657-86.
62. Bou G, Martinez-Beltran J. Cloning, nucleotide sequencing, and analysis of the gene encoding an AmpC β-lactamase in Acinetobacter baumannii. Antimicrob Agents Chemother 2000; 44(2): 428-32.
63. Rodriguez-Martinez JM, Nordmann P, Ronco E, Poirel L. Extended-spectrum cephalosporinase in Acinetobacter baumannii. Antimicrob Agents Chemother 2010; 54(8): 3484-8.
64. Tian GB, Adams-Haduch JM, Taracila M, Bonomo RA, Wang HN, Doi Y. Extended-spectrum AmpC in Acinetobacter baumannii: ADC-56 confers resistance to cefepime. Antimicrob Agents Chemother 2011; 55(10): 4922-5.
65. Bhattacharya M, Toth M, Antunes NT, Smith CA, Vakulenko SB. Structure of the extended-spectrum class C β-lactamase ADC-1 from Acinetobacter baumannii. Acta Crystallogr D Biol Crystallogr 2014; 70(Pt 3): 760-71.
66. Jeon JH, Hong MK, Lee JH, et al. Structure of ADC-68, a novel carbapenem-hydrolyzing class C extended-spectrum β-lactamase isolated from Acinetobacter baumannii. Acta Crystallogr D Biol Crystallogr 2014; 70(Pt 11): 2924-36.
67. Kleywegt GJ. Validation of protein crystal structures. Acta Crystallogr D Biol Crystallogr 2000; 56(Pt 3): 249-65.
68. Roth TA, Minasov G, Morandi S, Prati F, Shoichet BK. Thermodynamic cycle analysis and inhibitor design against β-lactamase. Biochemistry 2003; 42(49): 14483-91.
69. Drawz SM, Babic M, Bethel CR, et al. Inhibition of the class C β-lactamase from Acinetobacter spp.: insights into effective inhibitor design. Biochemistry 2010; 49(2): 329-40.
70. Beesley T, Gascoyne N, Knott-Hunziker V, et al. The inhibition of class C β-lactamases by boronic acids. Biochem J 1983; 209(1): 229-33.
71. Crompton IE, Cuthbert BK, Lowe G, Waley SG. β-lactamase inhibitors. The inhibition of serine β-lactamases by specific boronic acids. Biochem J 1988; 251(2): 453-9.
72. Morandi F, Caselli E, Morandi S, et al. Nanomolar inhibitors of AmpC β-lactamase. J Am Chem Soc 2003; 125(3): 685-95.
73. Schrodinger, LLC. The PyMOL Molecular Graphics System, Version 1.3r1. 2010.
74. Kumar S, Adediran A, Nukaga M, Pratt RF. Kinetics of turnover of cefotaxime by the Enterobacter cloacae P99 and GC1 β-lactamases: two free enzyme forms of the P99 β-lactamase detected by a combination of pre- and post-steady state kinetics. Biochemistry 2004; 43: 2664-72.
75. Vakulenko SB, Golemi D, Gery K, et al. Mutational replacement of Leu-293 in the Class C Enterobacter cloacae P99 β-lactamase confers increased MIC of cefepime. Antimicrob. Agents Chemother 2002; 46: 1966-1970.
76. Bauvois C, Ibuka AS, Celso A, et al. Kinetic properties of four plasmid-mediated AmpC β-lactamases. Antimicrob. Agents Chemother 2004; 49: 4240-46.